Relevium Announces Delayed Filing of Interim Disclosure Documents Pursuant to Temporary Relief Granted by Regulators due to C...
28 May 2020 - 7:11AM
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and
Frankfurt: “6BX”) (the “Company” or “Relevium”), today announced
that it will be delaying the filing and delivery of certain of its
continuous disclosure documents, in accordance with Decision No
2020-PDG-0023 of the Autorité des marchés financiers (Québec)
(the “
Exemption”),which was adopted for the
purpose of providing certain filing and other relief to issuers in
light of the challenges posed by the COVID-19 pandemic.
The Company is relying on the Exemption by
delaying the filing of its quarterly financial statements and
related management discussion and analysis for the period ended
March 31, 2020 required pursuant to National Instrument 51-102
Continuous Disclosure Obligations and the filing of the related
certifications(collectively, the "Required
Filings") and compliance with the delivery requirements of
applicable securities laws relating to the Required Filings. The
Company intends to file the Required Filings by July 14,
2020.Blackout in Effect for Management and Other
InsidersIn accordance with the Corporation's Securities
Trading Policy, the officers and directors of the Corporation and
certain other persons will remain subject to a trading black-out
pursuant to which such persons are prohibited from trading in any
securities of the Corporation until such time the Required Filings
are filed on SEDAR and a corresponding news release is issued by
the Corporation.About Relevium Technologies
Relevium is a publicly traded Company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operation of brands and businesses in
the health and wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition, and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including Walmart.com and
Amazon.com.
Biocannabix Health Corporation (BCX), based in
Montreal, Quebec, is a biopharma nutraceutical Company focused on
delivering pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking Statements
This release includes certain statements and
information that may constitute forward-looking information within
the meaning of applicable Canadian and United States securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions, or expectations of future
performance, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", or "would" occur.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek to rely on the
applicable safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES
INC
Email: investors@releviumcorp.com Website:
www.releviumtechnologies.com Like us on FacebookFollow us on
Twitter Follow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024